PMCPA Case Library

Every PMCPA ruling since 2005 — searchable and filterable by company, clause, and ABPI Code version.

1,930
Cases
291
Companies
154
Clauses
6
Code Versions

or browse all 154 ABPI clause guides ↗

Case Library Membership

Filter by Company & ABPI Clause

Search free — but unlock advanced filters to find every case involving a specific company or clause.

Filter 1,930+ cases by any of 291 companies
Filter by any of 154 ABPI Code clauses
Filter by Code version (2016, 2019, 2021…)
Full-text keyword search across all cases
Cancel any time

Already a member? Sign in →

Case Library Membership

Best value
£249 /year Save £99

inc. VAT

£29 /month

inc. VAT · cancel any time

Unlock Full Access →

Secure payment via Stripe


Need access for your team?

Company licences available for compliance teams, medical affairs, and training programmes.

Get a team quote →

1,930 cases found

19
Feb 2026
2024 Code

AI-Enabled MLR in Pharma: Governance First Guide

AI tools can enhance Medical affairs MLR workflows but pose governance challenges. It’s crucial to implement strict controls, maintain compliance with the…

18
Feb 2026
2021 Code AstraZeneca Clause 1 Clause 2 Clause 3 Clause 4 Clause 5 Clause 6 Clause 8 Clause 26

AstraZeneca: promotional meeting misclassified and LinkedIn ‘likes/reposts’ led to pre-authorisation promotion and public advertising concerns (AUTH/3729/1/23)

Six complaints against AstraZeneca. Breaches found for a UK meeting treated as non-promotional (certification/PI and ‘cure’ claims) and for LinkedIn engagement promoting…

12
Feb 2026

Blurred boundaries: Lessons from the Eli Lilly Facebook Breast Cancer Ad (CASE/3869/12/23)

TL;DR: Even a globally reputable company using trusted partners can stumble into serious compliance breaches online. All pharma professionals should be proactive,…

12
Feb 2026

The ripple effect of a single click: What Moderna’s mRESVIA PMCPA case really teaches us

Ever wondered how something as innocent as a LinkedIn ‘like’ could pull an entire pharma company into PMCPA hot water? I once…

12
Feb 2026

LinkedIn landmines: The hidden pitfalls of pharma social media

What 214 Social Media cases taught me about compliance risk I’ve just finished reviewing 214 PMCPA cases where social media played a…

12
Feb 2026
2024 Code

Beyond the headlines: What the Epidyolex Press Release ruling really teaches pharma teams

Let me take you behind the scenes of a Jazz Pharmaceuticals case that could have happened to any of us. In my…

12
Feb 2026
2024 Code

Last-minute decks and the competitor trap: ABPI Clauses 6 & 14 risk under pressure

Every congress season, the influx of last-minute speaker decks exposes a familiar vulnerability in pharmaceutical communications. Speed, while necessary, brings competitor risk…

12
Feb 2026

Pipeline transparency at medical booths: A defendable approach for todays congresses

Every spring and summer, the congress season breathes energy into the pharmaceutical world—a moment brimming with anticipation for product progress, emerging data,…

12
Feb 2026

Unpacking ‘Balance’ in the ABPI Code: Clearing the fog on the ABPIs favourite fuzzword

A brand manager surprised me when she asked me if the new ad was ‘balanced’. I think she said it with the…

12
Feb 2026
2024 Code

When “Supported by…” isn’t enough: The real risks of Pharma sponsorship declarations under the microscope

TL;DR: If your sponsorship declaration isn’t crystal-clear, up-front, and brutally honest about influence? It’s non-compliant. Tidy up your wording, lock in placement,…

12
Feb 2026
2024 Code

Perception is the new compliance: Navigating the ABPI Code shift in the real world

Let me tell you about a moment in 2024 that jolted me: an utterly compliant disease-awareness campaign unravelled because a single social…

12
Feb 2026
2024 Code

When “Non-Promotional” bites back: Navigating the hidden risks of the ABPI Code

I have seen the supposedly innocent disease-awareness flyers! If you think ‘non-promotional’ means ‘risk-free,’ you’re in for a surprise – and so…

12
Feb 2026

The ABPI Code at Christmas: what this year’s breaches really taught us (and how to start 2026 clearer, not quieter)

Tired teams, last-minute campaigns, and a swirl of regulatory updates — the Christmas run-up in pharma is always a mixing pot of…

12
Feb 2026
2024 Code

Why social media is high-risk for Pharma

I still remember the LinkedIn post that landed in my inbox at 7:30 a.m. — a well-meaning disease-awareness graphic shared by a…

12
Feb 2026

Inside the mind of an ABPI Final Signatory: Risk assessment isn’t a checklist

In this short piece I’ll step into the signatory seat and explain what risk assessment actually looks like when I review a…

1125126127128129

Ask questions about any PMCPA case

Our PMCPA rulings expert has knowledge of over 1,900 published cases — ask about precedents, clauses, and how they apply to your situation.

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free